Avtar Dhillon, MD: Chairman
Dr. Dhillon has served as a director of Arch Therapeutics, Inc. (OTCQB: ARTH), since May 2011 and was appointed Chairman in April 2013. Previously, Dr. Dhillon was the President and Chief Executive Officer of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation) (NYSE Euronext: INO) from October 2001 to June 2009, as President and Chairman of Inovio from June 2009 until October 2009, as Executive Chairman until August 2011, and as Chairman from September 2011. During his tenure at Inovio, Dr. Dhillon led the successfully turnaround of the company through a restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals to develop a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon led multiple successful financings for Inovio and concluded several licensing deals that included global giants, Merck and Wyeth (now Pfizer). Prior to joining Inovio, Dr. Dhillon was vice president of MDS Capital Corp. (now Lumira Capital Corp.), one of North America’s leading healthcare venture capital organizations. In July 1989, Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years. Dr. Dhillon has been instrumental in successfully turning around struggling companies and influential as an active member in the biotech community. From March 1997 to July 1998, Dr. Dhillon was a consultant to Cardiome Pharma Corp. (NASDAQ: CRME), where he lead a turnaround based on three pivotal financings, establishing a clinical development strategy, and procuring a new management team. In his role as a founder and board member of companies, Dr. Dhillon has been involved in several early stage healthcare focused companies listed on the USA or Canadian stock exchanges, which have successfully matured through advances in their development pipeline and subsequent M&A transactions. Most recently, he was a founding board member (May 2003) of Protox Therapeutics, Inc. (TSX-V: SHS) (now Sophiris Bio Inc.), a publicly traded specialty pharmaceutical company. Dr. Dhillon maintained his board position until the execution of a financing of up to $35 million with Warburg Pincus in November 2010. Dr. Dhillon currently sits on the Board of Directors of BC Advantage Funds, a Venture Capital Corporation in British Columbia, and since March 2012 has been the Chairman of Stevia First Corp. (OTCQB: STVF), an agricultural biotechnology company engaged in the cultivation and harvest of stevia leaf and the development of stevia products. Since March 2011, Dr. Dhillon has also served as the Chairman of OncoSec Medical, Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumor and metastatic cancers.
Arthur Rosenthal, PhD: Director
Dr. Rosenthal has been appointed as a director of the Company upon the consummation of the Merger, and has served as the Chairman of the Board of ABS since April 2011. He has served for 40 years in senior research and product development executive roles for medical technology companies and in those roles has successfully directed commercialization efforts for hundreds of novel medical products. He was Chief Scientific Officer at Boston Scientific from January, 1994 to January, 2005, Vice President of Research and Development at Johnson and Johnson Medical Products, Inc. from April, 1990 to January, 1994 and more recently Chief Executive Officer of two start-up companies, Labcoat, Ltd and Cappella, Inc., both developing cardiovascular medical devices . He is currently, and has been since January 2010, a Professor of Practice in Translational Research in Boston University’s College of Engineering, where he oversees biomedical engineering innovation. Dr. Rosenthal received his Ph.D. in biochemistry from the University of Massachusetts, Amherst, 1973. Currently, Dr. Rosenthal serves as Non Executive Director and Chairman, Compensation Committee and Audit Committee Member, Cyberonics, Inc., having joined the BOD in January 2007.
Terrence W. Norchi, MD: President, CEO, Director, Co-Founder
Terrence W. Norchi, MD is President and Chief Executive Officer of Arch Therapeutics, a company he co-founded in 2006 and led from an early stage of research to its current stage of development. Prior to Arch Therapeutics, Dr. Norchi was a portfolio manager, and pharmaceutical analyst, and head of the healthcare team at Putnam Investments. Previously, he was the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management. Prior to that he was s sell-side pharmaceutical analyst at Sanford C. Bernstein in New York City. He earned an M.B.A. from the MIT Sloan School of Management in 1996. Dr. Norchi completed internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as Chief Medical Resident. He earned an M.D. degree in 1990 from Northeast Ohio Medical University.
William M. Cotter: Chief Operating Officer
William M. Cotter has been advising Arch Therapeutics since 2011. He is an industry veteran who brings expertise in operations and product development in his role as advisor to Arch Therapeutics. Mr. Cotter has over 30 years of operational experience in Medical Devices, Diagnostics, Biologics and Life Science companies, ranging from early stage startups to large multinational corporations. Mr. Cotter has served in senior operations and development roles for companies including Cohera Medical, Helicos Biosciences, Closure Medical Corporation (Johnson & Johnson), Sanofi Diagnostics Pasteur (Beckman Coulter), Genetic Systems Corporation (Bio-Rad) and Advanced Technology Laboratories (Phillips HealthCare).
Mr. Cotter spent 10 years as VP Operations of Closure Medical Corp where he was part of the team that developed Dermabond, the world’s first synthetic topical skin adhesive approved by the FDA. He had direct responsibility and accountability for all product transfers from R&D, Engineering, Quality Control, Document Control, Production and Logistics. He was the development project leader and co-inventor of the Dermabond TSA ProPen delivery applicator, which won the 2004 Medical Design Excellence Gold Medal Award. He was an integral part of the Closure Medical senior management team that led to a successful acquisition by Johnson & Johnson.
Prior to Closure Medical, he spent 8 years with Sanofi Diagnostics Pastuer, where he had direct responsibility for all North American industrial sites and chaired the World Wide Manufacturing Committee for this International In-Vitro Diagnostics Company. Mr. Cotter is listed as co-inventor on 8 US patents and is a graduate of Ohio University.
Richard E. Davis: Chief Financial Officer
Mr. Davis brings a proven and successful record of more than 25 years of progressive and diversified business, financial and operational leadership within both publicly traded and privately held, domestic and multinational companies. Most recently, he has been an advisor to small and mid-size companies assisting them in their accounting, financial reporting, investor and banking needs. Prior to that, he was President, Chief Operating Officer and Chief Financial Officer at NMT Medical, Inc., a NASDAQ-traded medical device company. In this role he developed and executed strategic and operational plans that resulted in revenue growth of 35 percent, 13 consecutive quarters of profitability, increased stock price and analyst coverage from five major investment firms; directed the stabilization of a French subsidiary and led successful efforts in raising $6 million from institutional investors to fund ongoing FDA-approved clinical trials. Prior to that, he was Vice President and Chief Financial Officer at Q-Peak, Inc., where he oversaw all financial and administrative functions. Earlier, he worked in a variety of senior level positions at the Coleman Company, The TJX Companies, Inc. and Wang Laboratories. He holds a Master of Business Administration degree with a Finance concentration from Babson College and a Bachelor of Business Administration degree from the University of Massachusetts Amherst.
Chirag Shah, PhD: VP of R&D Engineering and Quality Systems
Chirag B. Shah, PhD is Vice President of Research and Development Engineering and Quality Systems at Arch Therapeutics. Dr. Shah brings broad 20 years of proven record of technology and product development, advanced research and device performance evaluations covering vascular, advanced wound care and infection control products. Prior to joining Arch Therapeutics, Dr. Shah was a Senior Director of Biomaterials R&D Center of Excellence in Vascular Therapies GBU at Covidien for 10 years and contributed to peripheral and neurovascular, wound care and renal access products and technologies development. Earlier, Dr. Shah worked at Biolink Corporation focusing on development of a liquid device product for infection and clotting prevention. Prior to that, Dr. Shah worked at USCI division of C.R. Bard, focusing on myocardial bioactive implant and thromboresistant stent coating technologies.
Dr. Shah earned a PhD from University of Rhode Island in 1993 and Executive Leadership Certificates from Cornell and MIT in 2011 and 2009, respectively. Dr. Shah is listed as co-inventor on 25 US issued patents and published applications.
Steven A. Kates, PhD: VP of Technology
Steven Kates, PhD has worked with Arch Therapeutics since 2007. He is a highly experienced pharmaceutical executive with over twenty years in R&D for both life science products and human therapeutics, Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to early clinical development. He was responsible for the successful development of clinical candidates for both 505(b)2 and NCE applications. He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation.
Dr. Kates has authored or co-authored over 100 articles, reviews, and patents, and is a member of the American Chemical Society, the American Peptide Society, and the Association of BioMolecular Research Facilities. Dr. Kates has served as editor of Solid-Phase Synthesis: A Practical Guide and ADMET for Medicinal Chemists: A Practical Guide; guest editor of Biopolymers; co-editor of ADMET for Medicinal Chemists, A Practical Guide; a member of the Editorial Board of International Journal of Peptide Research and Therapeutics (formerly Letters in Peptide Science); and is an ad hoc reviewer for the NIH bio-organic and natural products study section.
An Adjunct Professor in the Bouvé College of Health and Sciences, Center for Drug Discovery and College of Professional Studies at Northeastern University, and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in chemistry from Bates College and his Ph.D. in Synthetic Organic Chemistry from Brandeis University, and conducted post-doctoral studies at The Massachusetts Institute of Technology. His research interests include solid-phase peptide and organic synthesis as well as synthesis of peptides and small molecules with therapeutic activities for stroke, coronary artery bypass graft (CABG), myocardial infarction (MI) and inhibitors and substrates for kinases, proteases and G-protein coupled receptors.
Elaine Whitmore, PhD: VP of Regulatory Affairs
Elaine Whitmore, PhD., brings over 25 years of extensive history in the medical products industry to Arch Therapeutics, with whom she started working in late 2010 focusing on regulatory planning and strategy. In addition to regulatory submissions, Dr. Whitmore’s experience includes development, testing, technology evaluation, and clinical planning for a variety of hemostasis products (fibrin sealants; bovine, human and recombinant thrombin products; cellulose; collagen; etc.), adhesion prevention products, and infection prevention products.
Dr. Whitmore is the author of Development of FDA-Regulated Medical Products—A Translational Approach (ASQ Quality Press, 2012) and has numerous patents for medical product technologies. Prior to becoming a product development and technology consultant, she held executive management industry positions in a variety of functions, including New Product Development, Regulatory and Clinical Affairs, Scientific Affairs, and Business Development. Dr. Whitmore received her PhD degree from Northwestern University.